Gencurix Inc
229000
Company Profile
Business description
Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.
Contact
243 Digital-ro
15th floor, Jiha City
Guro-gu
Seoul
KORT: +82 7074329481
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,003.00 | 6.60 | 0.07% |
| CAC 40 | 8,364.65 | 25.69 | 0.31% |
| DAX 40 | 25,114.25 | 47.16 | 0.19% |
| Dow JONES (US) | 52,492.11 | 144.90 | -0.28% |
| FTSE 100 | 10,498.29 | 1.00 | 0.01% |
| HKSE | 24,213.72 | 38.60 | 0.16% |
| NASDAQ | 25,917.01 | 364.60 | -1.39% |
| Nikkei 225 | 67,242.73 | 1,315.00 | -1.92% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,523.31 | 52.08 | -0.69% |
| S&P/ASX 200 | 8,808.50 | 11.70 | 0.13% |
| SSE Composite Index | 3,913.79 | 82.37 | -2.06% |